Objective: To evaluate the effect and safety of Yimusake Tablets combined with dapoxetine hydrochloride and either of them used alone in the treatment of premature ejaculation (PE).

Methods: We randomly assigned 180 PE patients to oral medication of Yimusake Tablets at 1.5 g per night (group A), dapoxetine hydrochloride at 30 mg at 1-3 hours before anticipated sexual activity (group B), the Yimusake Tablets plus dapoxetine hydrochloride simultaneously (group C), all for 8 weeks. After 4 and 8 weeks of medication, we recorded and compared the changes in the intravaginal ejaculation latency time (IELT), measures of the PE profile (PEP), and adverse events among the three groups of patients.

Results: The treatment was accomplished and complete data obtained from 154 of the patients, 56 in group A, 52 in group B, and 46 in group C. After 4 and 8 weeks of medication, the mean IELT was dramatically prolonged in all the three groups as compared with the baseline (P<0.01), most significantly at 8 weeks in group C ([2.08±0.68] min), followed by B ([1.76±0.52] min) and A ([1.47±0.44] min), with statistically significant differences among the three groups (P<0.01). The PEP measures were remarkably improved in group A at 8 weeks (P<0.05), and both in B and C at 4 and 8 weeks (P<0.05), most significantly at 8 weeks in group C (P<0.05), in which the patients scored 1.96±0.77 in perception of control over ejaculation, 2.62±0.98 in satisfaction with sexual intercourse, 3.04±0.62 in PE-related distress, and 3.57±0.80 in PE-induced difficult relationship with their partners, all markedly improved as compared with groups A and B (P<0.05). Adverse reactions were observed in 2 cases (3.6%) in group A, 6 cases (9.6%) in B, and 5 cases (10.9%) in C. No severe adverse events occurred in any of the patients during the study.

Conclusions: Combined medication of Yimusake Tablets and dapoxetine hydrochloride, with its advantages of effectiveness and safety, deserves to be recommended for the treatment of PE.

Download full-text PDF

Source

Publication Analysis

Top Keywords

yimusake tablets
16
dapoxetine hydrochloride
16
safety yimusake
8
tablets dapoxetine
8
hydrochloride treatment
8
treatment premature
8
group weeks
8
weeks medication
8
three groups
8
group group
8

Similar Publications

Objective: To study of the regulatory effects of the lipid metabolic pathways of trimethylamine-N-oxide (TMAO), flavin-containingmonooxidase 3 (FMO3) and farnesoid X receptor (FXR) on compound stress-induced ED (CSED) rats and the mechanisms of Yimusake Tablets (YMSK) intervention.

Methods: Based on the results of metabonomics analysis, we determined the concentration of TMAO in the serum of the rats in the normal control (n = 30), the CSED model control (n = 30) and the YMSK intervention group (intragastrical administration of YMSK at 250 mg/kg once daily for 2-3 weeks after modeling, n = 30) by nuclear magnetic resonance (NMR) spectroscopy test. We also detected the expressions of the FMO3, FXR1 and FXR2 proteins in the liver tissue of the three groups of rats by Western blot.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to identify specific protein markers in rat penile tissue related to erectile dysfunction (ED) and assess the effectiveness of Yimusake Tablets (YT) as an intervention.
  • - Researchers conducted experiments on 80 male rats, dividing them into control, ED model, and YT treatment groups, and utilized advanced proteomics techniques to analyze protein expression.
  • - They discovered 48 proteins linked to ED in model control rats and 29 in YT-treated rats, identifying seven potential biomarkers associated with ED, which play roles in endothelial function, smooth muscle activity, inflammation, and glucose metabolism.
View Article and Find Full Text PDF

Objective: To determine the expressions of calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) in the penile tissue of the ED rat model and explore their action mechanisms.

Methods: An ED model was established in 44 mature male SD rats by feeding them on a spinach + coriander diet in a cold-wet environment and another 10 were taken as normal controls. Then the model rats were randomly divided into an ED model control group (n = 15) treated by gavage of distilled water in the same modeling environment, a spontaneous recovery group (n = 15) treated by gavage of distilled water in the normal environment, and a medication group (n = 14) treated intragastrically with Yimusake Tablets at 250 mg/kg qd.

View Article and Find Full Text PDF

Study on evaluation of toxicology and quality control of Yimusake tablet.

J Ethnopharmacol

December 2020

Key Laboratory of the Ministry of Education of Xinjiang Phytomedicine Resources Utilization, Pharmacy School of Shihezi University, Xinjiang Shihezi, 832002, Xinjiang, PR China. Electronic address:

Article Synopsis
  • The Yimusake tablet (YMSK-T) is a Xinjiang Uygur Medicine that shows potential in treating impotence and premature ejaculation by enhancing smooth muscle cell function.
  • The study aimed to assess the toxicology and quality control of YMSK-T, as its safety and effectiveness in clinical settings had not been previously evaluated.
  • High doses of YMSK-T caused severe damage to the myocardium and liver of rats, while lower doses exhibited no significant adverse effects on organ weight or blood parameters.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!